Content provided in partnership with

Small Startups Net Nearly $1m In Sbir Funding

Encelle Inc. of Raleigh, an emerging biomaterials company, has received a $100,000 Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to evaluate the company's proprietary hydrogel matrix, an injectable biopolymer material that has shown initial promise in wound healing.

"Encelle is developing wound-healing and other applications of its unique biomaterials technology," said James D. Woodward, Encelle's CEO. "This technology, originally discovered in the company's development of a bioartificial pancreas, is now the central focus of our development efforts."

Most Popular Articles in Technology: An overview of continuous data protection; Why all those current ratings?; Many countries now have a mobile penetration rate above 100%, report says; The Tata Group's big telecom gamble: VSNL's recent acquisition of Tyco ...; MEASURING BANK BRANCH EFFICIENCY USING DATA ENVELOPMENT ANALYSIS: MANAGERIAL ...; More »

Encelle recently filed an Investigational Device Exemption with the U.S. Food and Drug Administration and hopes to begin clinical trials later this year.

PPGx gets SBIR for bioinformatics

PPGx Inc. of Morrisville, a developer and supplier of research-based pharmacogenomic services and products, has received a Phase I SBIR grant from the U.S. Department of Health and Human Services.

The $98,934 grant will be used to develop a JAVA toolkit for analyzing data from micro-arrays in pharmacogenomic research studies. The Phase I program is designed to demonstrate the technical merit, feasibility and usefulness of applying Web-based visualization and analytical methods to uncover patterns of gene expression associated with drug addiction.

Though initially focused on long-term drug addiction, the software will help researchers study gene expression in a variety of other conditions. During the Phase I project, PPGx will work in close collaboration with scientists at the National Institute for Drug Addiction (NIDA) to establish user requirements, system design choices and specifications.

"PPGx is excited and truly honored to receive this research grant because it acknowledges and strengthens our ability to apply our bioinformatics expertise to critical issues confronting researchers and healthcare practitioners," said Josh Baker, Ph.D., president and chief executive officer of PPGx.

Paradigm Genetics awarded Phase II SBIR grant

Paradigm Genetics Inc. (Nasdaq: PDGM) of Research Triangle Park has received the second half of a Phase II SBIR grant from the U.S. Department of Energy for on-going gene discovery work.

The entire award under Phase II of the research grant is $750,000, bringing the combined total of Phase I and Phase II awards to $825,000.

"This research grant supports continuing development of our industrialized microbial pathogen program focused on defining gene function for key fungal pathogens," said John Ryals, CEO and president of Paradigm Genetics. "The gene function information we identify has the potential to benefit human health and crop production by facilitating the development of anti-fungal products."

Technology Industry

Small Startups Net Nearly $1m In Sbir Funding

BT Catalyst, Oct, 2000

Find Research Guides for:

Find Featured Titles for: News

Most Popular Articles in Technology

Most Popular Publications in Technology